Evaluation of QuantiFERON®-TB gold in-tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 7, 2010, Pages 834-840

  Sauzullo, I ^a   Mengoni, F ^a   Scrivo, R ^a   Valesini, G ^a   Potenza, C ^a   Skroza, N ^a   Marocco, R ^a   Lichtner, M ^a   Vullo, V ^a   Mastroianni, Claudio M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNF treatment; HIV infection; IFN release assays; Tuberculosis

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AGRICULTURAL WORKER; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BCG VACCINATION; BEHCET DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOLOGY; ITALY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PSORIASIS; QUANTIFERON TB GOLD IN TUBE; RHEUMATOID ARTHRITIS; SCREENING TEST; SENSITIVITY ANALYSIS; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; ADOLESCENT; CLINICAL TRIAL; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERFERON-GAMMA; ITALY; MALE; MASS SCREENING; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77953648660     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. Jensen P A, Lambert L A, Iademarco M F, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings. MMWR Recomm Rep 2005; 54: 1-141.
3. Horsburgh C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
4. Huebner R E, Schein M F, Bass J B. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-975.
5. Tissot F, Zanetti G, Francioli P, Zellweger J P, Zysset F. Infl uence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217.
6. Mazurek G H, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54 (RR-15): 49-55.
7. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
8. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007; 131: 1898-1906.
9. Sauzullo I, Mengoni F, Lichtner M, et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferongamma T-cell response. PLoS One 2009; 4: e5187.
10. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
11. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207.
12. Landis J R, Koch G G. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
13. Health Protection Agency Tuberculosis Programme Board. Health protection agency position statement on the use of interferon gamma release assay (IGRA) tests for tuberculosis (TB): interim HPA guidance. London, UK: Health Protection Agency, 2008. http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/ 1191942150139 Accessed February 2010.
14. Domínguez J, Latorre I, Altet N, et al. IFN-γ-release assays to diagnose TB infection in the immunocompromised individual. Expert Rev Respir Med 2009; 3: 309-327.
15. Lange C, Pai M, Drobniewski F, Migliori G B. Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly? Eur Respir J 2009; 33: 1250-1253.
16. Sauzullo I, Mengoni F, Lichtner M, et al. QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. Diagn Microbiol Infect Dis 2008; 62: 395-401.
17. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen L, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7: 56-65.
18. Luetkemeyer A, Charlebois E, Flores L, et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
19. Jones S, de Gijsel D, Wallach F R, Gurtman A C, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold In-Tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007; 11: 1190-1195. (Pubitemid 350146299)
20. Dheda K, Lalvani A, Miller R F, et al. Performance of a T-cell- based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19: 2038-2041. (Pubitemid 41669032)
21. Stephan C, Wolf T, Goetsch U, et al. Comparing QuantiFERONTB Gold, T-SPOT tuberculosis and tuberculin skin test in HIVinfected individuals from a low prevalence tuberculosis country. AIDS 2008; 22: 2471-2479.
22. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
23. Moiton M P, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect 2006; 12: 1151-1153.
24. Gómez-Reino J J, Carmona L, Valverde V R, Mola E M, Montero M D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
25. Keane J, Breshinan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20: 443-449.
26. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and TST are both useful for latent TB screening in autoimmune diseases. Eur Respir J 2009; 33: 586-593.
27. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-781. (Pubitemid 351747116)
28. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-913.
29. Greenberg J D, Reddy S M, Schloss S G, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008; 35: 770-775.
30. Matulis G, Juni P, Villiger P M, Gadola S D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen specific interferon-γ assay. Ann Rheum Dis 2008; 67: 84-90.
31. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis A J. Usefulness of enzyme-linked immunospot assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35: 1271-1276. (Pubitemid 352000770)
32. Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009; 13: 1427-1432.